Andrew Hong, MD


Primary Specialty



Board Certification
Am Bd Pediatrics (Sub: Pediatric Hematology-Oncology), American Board of Pediatrics
Medical School:
Pritzker School of Medicine at the University of Chicago
Boston Childrens Hosipital
Dana-Farber Cancer Institute


Pubmed Profile



Andrew Hong, MD, joined Children’s Healthcare of Atlanta and Emory University School of Medicine as an Assistant Professor of Pediatrics with an Endowed Invesitgatorship in March 2020. He came to Atlanta, Ga., from Boston, Mass., where he was on the faculty at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as an instructor of pediatrics.

Prior to being a faculty member, Dr. Hong earned his undergraduate degree from the University of Chicago. He was recruited by McKinsey & Company as a business analyst. After several years, Dr. Hong received a Post-Baccalaureate Intramural Research Training Award from the National Cancer Institute (NCI) to perform yeast genomics under Munira Basrai, PhD, at the Center for Cancer Research. He returned to The University of Chicago Pritzker School of Medicine, where he earned his medical degree. While in medical school, his research focused on studying sirtuins under Raul Mostoslavsky, MD, PhD; David Lombard, PhD; and Frederick Alt, PhD, at Boston Children’s Hospital, studying breast cancer risk under Funmi Olopade, MD, at The University of Chicago.

Dr. Hong completed his pediatrics internship and residency at Boston Children’s Hospital and Boston Medical Center. He then completed a fellowship in pediatric hematology and oncology at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Afterwards, Dr. Hong became an instructor in pediatrics at Harvard Medical School, while also completing his post-doctoral fellowship under William C. Hahn, MD, PhD, at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Broad Institute and Massachusetts Institute of Technology.

Dr. Hong has broad clinical experience across pediatric oncology. His research ( is focused on high-risk solid tumors (e.g., kidney cancers, soft tissue sarcomas and brain tumors). These cancers represent the areas of greatest need in pediatric oncology. His work uses functional genomic techniques (e.g., RNAi and CRISPR-Cas9) and the latest sequencing technologies (e.g., long-range phased sequencing, scRNAseq and ATACseq) to identify new therapeutics and mechanisms in pediatric cancers.

His work has been funded by several groups, such as the National Cancer Institute (NCI), U.S. Department of Defense, American Cancer Society, American Association for Cancer Research, CureSearch for Children’s Cancer, Alex’s Lemonade Stand Foundation and Cure ATRT.

Focus of Practice

  • Solid tumors
  • Renal (kidney) tumors
  • Rare tumors

Areas of Interest

  • SMARCB1 deficient cancers rhabdoid tumor, renal medullary carcinoma, ATRT, epithelioid sarcoma, chordoma)
  • Wilms tumor
  • Rare tumors
  • Functional genomics
  • Developmental therapeutics


Aflac Cancer and Blood Disorders Center

Egleston Hospital, 1405 Clifton Road NE Atlanta, GA 30322 Get Directions 404-785-3240

Research & Publications

Dr. Hong’s research ( focuses on SMARCB1 deficient cancers (rhabdoid tumor, renal medullary carcinoma, ATRT, epithelioid sarcoma, chordoma), Wilms tumor, rare tumors, functional genomics and developmental therapeutics.